Education
About Us
Working with TipRanks
Follow Us
Castle Biosciences (CSTL)
NASDAQ:CSTL
CSTL Stock Chart & Stats
$25.50
-$0.86(-2.67%)
At close: 4:00 PM EST
$25.50
-$0.86(-2.67%)
Day’s Range― - ―
52-Week Range$14.59 - $35.84
Previous CloseN/A
Volume108.23K
Average Volume (3M)261.17K
Market Cap
$739.71M
Enterprise Value$364.73M
Total Cash (Recent Filing)$275.93M
Total Debt (Recent Filing)$37.35M
Price to Earnings (P/E)―
Beta1.12
Next Earnings
Nov 03, 2025EPS Estimate
-0.52Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding29,008,282
10 Day Avg. Volume236,861
30 Day Avg. Volume261,173
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.49
Enterprise Value/Revenue1.05
Enterprise Value/Gross Profit1.31
Enterprise Value/Ebitda14.57
Forecast
1Y Price Target
$32.91Price Target Upside29.06% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Bulls Say, Bears Say
Bulls Say
Financial PerformanceNon-dermatology test revenue grew approximately 65% year-over-year, driven by TissueCypher.
Market ExpansionAcceptance of CSTL's request for reconsideration by Novitas as well as continued generation of new supporting data could signal potential Medicare coverage for DecisionDx-SCC in the near term.
Regulatory ApprovalRecent sales incentive refocus and potential FDA approval could help drive higher adoption levels over time.
Bears Say
Castle Biosciences News
CSTL FAQ
What was Castle Biosciences’s price range in the past 12 months?
Castle Biosciences lowest stock price was $14.59 and its highest was $35.84 in the past 12 months.
What is Castle Biosciences’s market cap?
Castle Biosciences’s market cap is $739.71M.
When is Castle Biosciences’s upcoming earnings report date?
Castle Biosciences’s upcoming earnings report date is Nov 03, 2025 which is today.
How were Castle Biosciences’s earnings last quarter?
Currently, no data Available
Is Castle Biosciences overvalued?
According to Wall Street analysts Castle Biosciences’s price is currently Undervalued.
Does Castle Biosciences pay dividends?
Castle Biosciences does not currently pay dividends.
What is Castle Biosciences’s EPS estimate?
Castle Biosciences’s EPS estimate is -0.52.
How many shares outstanding does Castle Biosciences have?
Castle Biosciences has 29,008,282 shares outstanding.
What happened to Castle Biosciences’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Castle Biosciences?
Currently, no hedge funds are holding shares in CSTL
Castle Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$32.91 (29.06% Upside)
$32.91 (29.06% Upside)
Blogger Sentiment
Bullish
CSTL Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 68.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $390.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.5%
Last 30 Days ▲ 2.2%
Last 30 Days ▲ 2.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-26.44%
12-Months-Change
Fundamentals
Return on Equity
-2.15%
Trailing 12-Months
Asset Growth
11.78%
Trailing 12-Months
Company Description
Castle Biosciences
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.
CSTL Company Deck
CSTL Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed picture with significant growth in test volumes and successful collaborations, but also highlighted challenges in dermatological test revenues and reimbursement issues. Despite these challenges, Castle Biosciences raised its revenue guidance for the year, indicating optimism about future growth.View all CSTL earnings summariesCSTL Stock 12 Month Forecast
Average Price Target
$32.91
▲(29.06% Upside)
Technical Analysis
Ownership Overview
2.61% Insiders
28.97% Mutual Funds
0.10% Other Institutional Investors
54.54% Public Companies and
Individual Investors